Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-16
2011-08-16
Gupta, Anish (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S449000, C514S183000, C549S354000, C549S346000, C549S200000
Reexamination Certificate
active
07999002
ABSTRACT:
The invention relates to the use of a compound of the formula (I)or a pharmaceutically acceptable addition salt thereof for the preparation of a medicament for the prophylaxis and/or treatment of muscular dystrophy.
REFERENCES:
patent: 5780244 (1998-07-01), Engvall et al.
patent: 5780500 (1998-07-01), Betschart et al.
patent: 5780501 (1998-07-01), Betschart et al.
patent: 5863743 (1999-01-01), Campbell et al.
patent: 7078379 (2006-07-01), Ruegg
patent: 2009/0176867 (2009-07-01), Meier
patent: 2168937 (1996-02-01), None
patent: 0 726 265 (1996-08-01), None
patent: WO 00/49011 (2000-08-01), None
McGowan et al., “Laminins and Human Disease,” Microscopy Research and Technique 51, 262-79 (2000).
Waldmeier et al., “GCP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease,” Naunyn-Schmiedeber's Arch. Pharmacol. 362, 526-37 (2000).
Urtizberea, “Therapies in Muscular Dystrophy: Current Concepts and Future Prospects,” Eur. Neurol. 43, 127-32 (2000).
“The muscular dystrophies,” by Emery, Lancet 359, 687-95 (2002).
Definition of “Prophylaxis,” Stedman's Medical Dictionary, 26th Ed., Williams & Wilkins (Baltimore), p. 1439 (1995).
“Glyceraldehyde-3-phosphate Dehydrogenase, the Putative Target of the Antiapoptotic Compounds CGP 3466 and R-(−)-Deprenyl” by Kragten et al., J. Biol. Chem. 273, 5821-28 (1998).
“Merosin-deficient Congenital Muscular Dystrophy: Partial Genetic Correction in Two Mouse Models” by Kuang et al., J. Clin. Invest. 102, 844-52 (1998).
International Search Report for PCT/EP2006/008237 dated Nov. 23, 2006.
Andringa et al., “TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates,” Neurobiology of Disease, vol. 14, 2003, pp. 205-217.
Meier Thomas
Ruegg Markus A.
Gupta Anish
Kilyk & Bowersox P.L.L.C.
Santhera Pharmaceuticals (Schweiz) AG
West Theodore R
LandOfFree
Use of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2658987